Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy.

Citation data:

F1000Research, ISSN: 2046-1402, Vol: 6

Publication Year:
2017
Usage 1
Link-outs 1
Captures 16
Readers 16
Social Media 1
Shares, Likes & Comments 1
PMID:
28413612
DOI:
10.12688/f1000research.9692.1
Author(s):
Ghazi, Lama, Drawz, Paul
Publisher(s):
F1000 Research, Ltd.
Tags:
Biochemistry, Genetics and Molecular Biology, Immunology and Microbiology, Pharmacology, Toxicology and Pharmaceutics
review description
The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN) with effects on vascular tone, sodium retention, oxidative stress, fibrosis, sympathetic tone, and inflammation. Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will (1) examine new anti-hypertensive medications affecting the RAAS, (2) evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and (3) review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice.

This review has 0 Wikipedia mention.